Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated ...

Microsoft and Bristol Myers Squibb have signed a new pact aimed at identifying lung cancer cases more quickly. | Microsoft ...

When lung cancer treatment stops working, what happens next? New research reveals the answer may depend on how the cancer grows.

Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell lung cancer. The OptiTROP-Lung05 study is the first phase 3 trial of an ...

Anktiva, also known as nogapendekin alfa inbakicept, is a new cancer therapy that boosts the immune system to target cancer ...

Dual Versus Single Checkpoint Inhibition in Advanced Non-Small Cell Lung Cancer: A Pooled Patient-Level Analysis of Six ...

The first patient has been dosed in the TROPION-Lung17 phase 3 trial evaluating DATROWAY® (datopotamab deruxtecan) compared ...

The partnership aims to deploy AI capabilities that automatically analyse X-ray and CT images to assist radiologists.

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its potential to improve treatment outcomes. The designation is based on phase 1 ...

Jared Weiss, MD, reveals the lessons taught by a mentor, Dr Corey Langer, in the care of patients with non–small cell lung cancer (NSCLC), extending from the overcoming of "clinical distance" between ...